SHARE – workpackage 5: evidence based recommendations for diagnosis and treatment of juvenile localized scleroderma and juvenile systemic sclerosis

Roberta Culpo,Clarissa Pilkington,Angelo Ravelli,Annett Van Royen,Francesco Zulian,Eileen Baildam,Ivan Foeldvari,Ricardo Russo,Jeffrey Chaitow,Sheila Oliveira ,Jordi Antón ,Tadej Avčin ,Özgür Kasapçopur ,Nico Wulffraat,Tamás Constantin ,C Boros ,Pavla Doležalová ,Claudia Saad‐Magalhães ,Sj Vastert ,Nataša Toplak

doi:10.1186/1546-0096-12-s1-p117

Abstract

Juvenile Localized Scleroderma (JLS) and Juvenile Systemic Sclerosis (JSSc) form a group of rare pediatric diseases that can lead to significant morbidity. Evidence-based guidelines are sparse and management is mostly based on physician’s experience. Consequently, treatment regimens differ throughout Europe. In 2012, a European initiative called SHARE (Single Hub and Access point for pediatric Rheumatology in Europe) was launched to optimize and disseminate diagnostic and management regimens in Europe for children and young adults with rheumatic diseases.

Highlights

form a group of rare pediatric diseases that can lead to significant morbidity
management is mostly based on physician's experience
treatment regimens differ throughout Europe

Summary

Introduction

Juvenile Localized Scleroderma (JLS) and Juvenile Systemic Sclerosis (JSSc) form a group of rare pediatric diseases that can lead to significant morbidity. Evidencebased guidelines are sparse and management is mostly based on physician’s experience. In 2012, a European initiative called SHARE (Single Hub and Access point for pediatric Rheumatology in Europe) was launched to optimize and disseminate diagnostic and management regimens in Europe for children and young adults with rheumatic diseases

Methods

Results

Conclusion